Literature DB >> 35704494

Darolutamide in Metastatic Prostate Cancer. Reply.

Matthew R Smith1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35704494     DOI： 10.1056/NEJMc2205310

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Darolutamide combo is an ARASENSible option for mHSPC.

Authors:  Annette Fenner
Journal:  Nat Rev Urol       Date:  2022-04       Impact factor: 14.432

2.  Androgen receptor pathway inhibitor combination in prostate cancer.

Authors:  Kelvin Yan
Journal:  Nat Rev Urol       Date:  2022-10       Impact factor: 16.430

3.  Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer.

Authors:  Kenneth Chen; Louise Kostos; Arun A Azad
Journal:  World J Urol       Date:  2022-08-27       Impact factor: 3.661
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.